Navigation Sciences’ team combines leadership in thoracic surgery and advanced surgical navigation technology, with Medtech business and finance expertise.
Alan D. Lucas
Co-Founder, CEO, and Director
Alan has served in senior business development and marketing positions at development stage and emerging medical technology companies for more than 25 years. He has global senior management experience enhancing investor value, including execution of successful fund raising through IPOs, private placements, and cross border M&A transactions. His experience includes work at Alira Health, EnlightenVue, Simplicity Orthopedics, ABIOMED, Implant Sciences, Kirschner Orthopedics and ACUFEX MicroSurgical.
Raphael Bueno M.D.
Co-founder, Director and Chair, Scientific Advisory Board, Chief, Thoracic Surgery, Brigham & Women's Hospital | Professor of Surgery, Harvard Medical School
Raphael Bueno, MD is the Chief of Thoracic Surgery, the Fredric G Levin Distinguished Chair in Thoracic Surgery and Lung Cancer Research, and Co-Director of the Lung Center at the Brigham and Women’s Hospital in Boston. He is also a Professor of Surgery at Harvard Medical School. He leads one of the largest comprehensive divisions of thoracic surgery in the US, which is responsible for nearly 5,000 cases per year. Dr. Bueno’s basic research is focused on developing molecular biomarkers in mesothelioma and lung cancer as well as using genomic strategies to expand therapies for these malignancies. His clinical research is focused on developing new strategies to target small lung nodules and GGOS as well as engineer innovative clinical trials using biological and immune therapies for thoracic cancer.
Jayender Jagadeesan Ph.D.
Co-Founder and Member, Scientific Advisory Board | Associate Professor of Radiology, Brigham & Women's Hospital, Harvard Medical School
Dr. Jayender Jagadeesan is an Associate Professor at Harvard Medical School, Research Associate at the Brigham and Women’s Hospital and Associate Member of the Broad Institute. His research interests include image-guided therapy, surgical navigation, robotics, modeling and control of smart materials, and haptics. Minimally Invasive Surgical devices and applications form his primary research motivation. He is also the technical lead for several surgical procedures in the state-of-the-art Advanced Multimodality Image-guided Operating (AMIGO) suite at BWH.
Giacomo Basadonna M.D., Ph.D.
Director and Member, Scientific Advisory Board | Professor of Surgery at the University of Massachusetts Medical School | Managing Director, Medical Affairs, Alira Health
Giacomo is a member of 23 national committees, 3 hospital committees and 14 professional societies. His previous hospital appointments include UC Davis Medical Center, Yale New Haven Hospital, and UMass Memorial Hospital. Additionally, Giacomo has held Chief Medical Officer positions at several companies, including Z-Medica. Giacomo holds an M.D. and Ph.D. from the University of Milan. His publications include over 80 abstracts, 13 limited dissertations, and over 80 publications in peer review journals.
Carl M Berke, Ph.D.
Director | Partner, Mass General Brigham Venture Fund | Founding Director of Mass Medical Angels LLC
Carl’s career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. Prior to Mass General Brigham, he served as a Partner at Integral/Analysis Group, a management consultancy focused on innovation strategy. Previously, he was a bench scientist and R&D director at Polaroid Corporation and Hygeia Sciences, where he worked on the development of photographic and clinical diagnostic products. He is an inventor on six U.S. patents. Carl has served on the board of directors of companies spanning multiple biomedical technologies, including: Quosa, Kasalis, Annovation, Combinent Sebacia, Infobionic, QPID Health, LifeImage, Syntimmune, Argo Cardiovascular, Walden Bioscience, Pykus Therapeutics Starlight Cardio, Lyndra, SeQure Dx and the philanthropic Sudanese Education Fund. Carl holds an AB degree from Cornell University and received his Ph.D. in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the in the Harvard-MIT Health Sciences and Technology Division.
Steve Gullans, Ph.D.
Director | Principal at Gullans Advisory, LLC
Steve is an experienced biotech executive, venture investor, scientist, entrepreneur, and author. Throughout his career he has focused on building companies to translate scientific advances into solutions for patients and providers. He currently advises life science companies on strategy and financings. Previously, he was CEO of Gemphire Therapeutics, Inc., a public biotech which he joined after 10 years as a Managing Director at Excel Venture Management, a firm he co-founded, and which has invested $225M across more than 40 life science companies. At Excel, Steve served as a Board Director of more than a dozen private and public biotech, medtech, diagnostics, and health IT companies, with many successful exits. Prior to Excel, Steve held CEO and CSO positions at two life sciences companies. Steve is currently a Director at Orionis Biosciences and iSpecimen which recently went public on the Nasdaq [ISPC].
Steve began his career as a professor at Harvard Medical School and Brigham & Women’s Hospital, where he published more than 130 scientific papers and was elected a Fellow of the American Association for the Advancement of Science (AAAS) and of the American Heart Association (AHA). He was an advisor to the Innovation Groups at the Cleveland Clinic and Mass General Brigham. He received his Ph.D. from Duke University, post-doctoral training at Yale University, and his B.S. from Union College.
David Fogel, CPA
Chief Financial Officer
David’s expertise lies in constructing a reliable financial framework to attract funding. He possesses over thirty years of senior financial management experience in various capacities for a variety of medical device, life sciences, and healthcare related companies, including GSI Lumonics, Glympse Bio, Infobionic, Confer Health, and Third Pole Therapeutics. He is a contributor to the entrepreneurial ecosystem as an active presenter and panelist with, among others, TechStars, MassChallenge, and MIT Enterprise Forum. David is an active member of the angel investor community and has a BS from Miami University (Ohio), and an MBA from the University of Cincinnati. David is a licensed Certified Public Accountant (CPA) and is an adjunct instructor in the MBA program teaching Entrepreneurial Finance at Northeastern University.
Scientific Advisory Board
T. Forcht Dagi, M.D., D.Med.Sc, D.H.C, F.R.C.S.Ed
Member, Scientific Advisory Board. Professor, Queen’s University Belfast | Senior Consultant, Mayo Clinic College of Medicine and Science | Senior Managing Partner, ROSC Global LLC
T. Forcht (Teo) Dagi is a neurosurgeon and served until recently as chairman of the School of Medicine, and later the School of Management of Queen’s University Belfast. He is also a Senior Consultant to the Mayo Clinic College of Medicine and Science. Before that, he was a director of the Harvard-MIT Program in Biomedical Entrepreneurship. His recent research has focused on surgical instrumentation, innovation and translation, and on patient safety. He is an International Surgical Advisor for the Royal College of Surgeons of Edinburgh, sits on its Surgical Specialty Board in Neurosurgery, is a Director of the American Association of Neurological Surgeons and an Editor of Neurosurgery. He was CEO of Boston Neurosciences and a board member of the Massachusetts Life Sciences Council. He currently leads the life sciences practice at ROSC Global, LLC.
David Feller-Kopman, M.D., FCCP
Chief, Pulmonary and Critical Care Medicine Dartmouth-Hitchcock Medical Center, Professor of Medicine Geisel School of Medicine
Dr. Feller-Kopman is the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center and a Professor of Medicine at the Geisel School of Medicine. His areas of clinical expertise include all aspects of interventional pulmonology, including minimal invasive diagnostic procedures to evaluate suspicious lung nodules and enlarged lymph nodes in the chest as well as the evaluation and management of malignant and non-malignant central airway obstruction. In addition, he specializes in the evaluation and management of pleural diseases with minimally invasive procedures such as ultrasound guided thoracentesis, indwelling pleural catheters and thoracoscopy with pleurodesis. He is a fellow of the American College of Chest Physicians and a member of the American Thoracic Society, the American Association for Bronchology and Interventional Pulmonology and the Miller-Coulson Academy of Clinical Excellence at Johns Hopkins.
Robert J. McKenna, M.D.
Robert J. McKenna, M.D., Chief of Thoracic Surgery St. Johns Health Center | Professor of Surgery, Saint John’s Cancer Institute | Professor of Thoracic Surgery, Stanford University
Robert McKenna, M.D., is a board-certified thoracic surgeon who pioneered minimally invasive lung cancer surgery. He has taught many thoracic surgeons around the world how to perform this surgery. With nearly 30 years of experience, Dr. McKenna is well-respected in the medical community for his clinical and research contributions. Dr Mckenna joined Providence Medical Institute in Santa Monica in November 2015.
Dr. McKenna has published more than 250 peer-reviewed articles and has authored two books and 48 book chapters on topics related to his specialty. Dr. McKenna has presented his research findings to both national and international audiences. He is a member of the Society of Thoracic Surgeons and the American Association for Thoracic Surgery.